Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies

纤维化发病机制和解决：从机制到治疗

• 批准号: 10678808
• 负责人: TERRY L. SHEPPARD
• 金额: $ 0.5万
• 依托单位: KEYSTONE SYMPOSIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-15 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10678808
• 关键词: 2019-nCoV; Acceleration; Address; Aging; Alberta province; Area; Automobile Driving; Biological Markers; Biological Process; Biotechnology; Canada; Career Mobility; Cessation of life; Chronic; Cicatrix; Clinical; Clinical Trials; Collaborations; Development; Diagnosis; Disease; Education; Educational workshop; Epigenetic Process; Event; Fibroblasts; Fibrosis; Fostering; Growth; Health Care Costs; Healthcare Systems; Heterogeneity; Human; Industry; Infectious Agent; Injury; Institution; Joints; Knowledge; Learning; Link; Liver Fibrosis; Metabolic; Methodology; Molecular; Natural regeneration; Oncogenic; Organ; Organ failure; Outcome; Participant; Pathogenesis; Pharmaceutical Preparations; Pharmacologic Substance; Physicians; Population; Research; Research Personnel; Resolution; Safety; Scientist; Speed; Symptoms; Technology; Therapeutic; Tissues; Translating; Translations; Trauma; Virus Diseases; Work; antifibrotic treatment; bench to bedside; career; clinical practice; cost; design; drug discovery; healing; improved; multidisciplinary; next generation; non-alcoholic fatty liver disease; nonalcoholic steatohepatitis; novel; novel strategies; posters; response; symposium; tissue repair

ABSTRACT Support is requested for a Keystone Symposia conference entitled Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, organized by Drs. David Lagares, Boris Hinz and Carine Boustany. The conference will be held in Banff, Alberta, Canada from March 19 - 23, 2023. Human fibrotic diseases are characterized by progressive tissue scarring in response to overwhelming or chronic injury, ultimately leading to organ failure and death. Fibrotic diseases cause healthcare costs reaching $10 billion per year. These costs are expected to further increase with our aging populations, our increasing capacity to diagnose fibrotic disorders and the emergence of novel infectious agents such as SARS-CoV-2, which can promote the development of fibrosis. Therefore, this conference was designed to identify common and distinct mechanisms driving fibrosis in response to different insults (e.g., viral infection, trauma, oncogenic injury). This conference will also address the following emerging themes in the field: 1) the mechanisms which amplify and perpetuate tissue fibrosis, such as aging, epigenetics, and mechanobiology, 2) the relevance of fibroblast heterogeneity in tissue repair and fibrosis, and 3) understanding the mechanisms promoting fibrosis resolution and regeneration to devise novel strategies to truly regenerate fibrotic organs. This forum will also focus on major clinical challenges including the lack of robust fibrosis biomarkers, safety endpoints, and clinical trial endpoints. Advances in these areas will break down barriers in translating anti-fibrotic therapies from bench to bedside. This Keystone Symposia conference will accelerate fibrosis research and anti-fibrotic drug discovery by fostering interdisciplinary interactions among a diverse group of physicians and scientists from both academic institutions and the pharmaceutical and biotech industry. Finally, this conference will be held jointly with Metabolic and Molecular Mechanisms of NAFLD/NASH. The joint conference will highlight current evidence linking key biological processes involved in NASH and liver fibrosis. Participants from both conferences will have the opportunity to network through shared sessions, mealtimes, and evening poster sessions.

抽象的 请求支持题为“纤维化发病机制和解决方案”的 Keystone 研讨会： 从机制到疗法，由 Drs 组织。大卫·拉加雷斯、鲍里斯·欣茨和卡琳·布斯塔尼。这 会议将于2023年3月19日至23日在加拿大艾伯塔省班夫举行。 人类纤维化疾病的特点是进行性组织疤痕响应压倒性或 慢性损伤，最终导致器官衰竭和死亡。纤维化疾病导致医疗费用达到 每年 100 亿美元。随着人口老龄化、人口老龄化和人口老龄化，这些成本预计将进一步增加。 诊断纤维化疾病和新型传染源（例如 SARS-CoV-2）的出现的能力， 从而可以促进纤维化的发展。因此，本次会议旨在确定共同点 以及响应不同损伤（例如病毒感染、创伤、致癌性）而驱动纤维化的不同机制 受伤）。本次会议还将讨论该领域的以下新兴主题：1） 放大和延续组织纤维化，例如衰老、表观遗传学和机械生物学，2） 组织修复和纤维化中成纤维细胞的异质性，3) 了解促进纤维化的机制 分辨率和再生来设计真正再生纤维化器官的新策略。本次论坛还将 专注于主要的临床挑战，包括缺乏强大的纤维化生物标志物、安全终点和临床 试验终点。这些领域的进展将打破将抗纤维化疗法转化为药物的障碍。 长凳到床边。本次Keystone Symposia会议将加速纤维化研究和抗纤维化药物 通过促进不同群体的医生和科学家之间的跨学科互动来发现 学术机构以及制药和生物技术行业。最后，这次会议将举行 与 NAFLD/NASH 的代谢和分子机制相结合。联席会议将重点关注当前 将 NASH 和肝纤维化相关的关键生物过程联系起来的证据。双方参与者 会议将有机会通过共享会议、用餐时间和晚间海报进行交流 会议。